Drug intelligence / Profile preview

DREP-HIV-PT1 + CN54gp140 + MPLA-L

Development stage: Unknown
Lead developer: Medical Research Council
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

A prophylactic HIV vaccine candidate consisting of HIV Clade C DREP-HIV-PT1 (a DNA-launched replicon) administered in combination with CN54gp140 (a recombinant HIV envelope protein from the clade C 97/CN/54 isolate) formulated with MPLA-L adjuvant. This combination is being evaluated for safety and immunogenicity in healthy HIV-uninfected adults.

Other names: DREP-HIV-PT1 + CN54gp140/MPLA-L-ANRS

Targets

BCR (Immunoglobulin G B Cell Receptor)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on DREP-HIV-PT1 + CN54gp140 + MPLA-L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DREP-HIV-PT1 + CN54gp140 + MPLA-L.

Explore the full profile